However, actinomycin D is non-specific inhibitor for BCR/ABL transcription, thus we used another specific inhibitor of tyrosine kinases, which is activated by BCR/ABL protein in CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.